Improved postprandial glycemic control with insulin aspart: A randomized double-blind cross-over trial in type 1 diabetes

Diabetes Care

Volumn 22, Issue 5, 1999, Pages 801-805

  Lindholm, Anders ^a   McEwen, John ^b   Riis, Anders P ^a  

^a NOVO NORDISK A S   (Denmark)

^b Drug Development Diabetes Novo Nordisk A/S ^*

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN INSULIN; INSULIN; INSULIN ASPART; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHEMICAL ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES CONTROL; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; MALE; PHARMACODYNAMICS; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032896693     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.22.5.801     Document Type: Article

References (24)

1. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and the progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-978, 1993
2. Reichard P, Nilsson BY, Rosenqvist U: The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 329:304-309, 1993
3. Wiseman MJ, Saunders AJ, Keen H, Viberti GC: Effect of blood glucose control on increased glomerular filtration rate and kidney size in insulin-dependent diabetes. N Engl J Med 312:617-621, 1985
4. Wang PH, Lau J, Chalmers TC: Meta-analysis of effects of intensive blood-glucose control on late complications of type 1 diabetes. Lancet 341:1306-1309, 1993
5. Hirsch IB, Farkas-Hirsch R, Skyler JS: Intensive insulin therapy for treatment of type 1 diabetes. Diabetes Care 13:1265-1283, 1990
6. Binder C: Absorption of injected insulin. Acta Pharmacol Toxicol 27 (Suppl. 2): 1-84, 1969
7. Binder C, Lauritzen T, Faber O, Pramming S: Insulin pharmacokinetics. Diabetes Care 7:188-199, 1984
8. Owens DR: Human Insulin. Lancaster, U.K., MTP, 1986
9. Home, PD: Insulin therapy. In The International Textbook of Diabetes. 2nd ed. Alberti KGMM, Zimmet P, DeFronzo RA, Eds, Chichester, U.K., Wiley, 1996, p. 899-928
10. Blundell T, Dodson G, Hodgkin D, Mercola D: Insulin: the structure in the crystal and its reflection in chemistry and biology. Adv Protein Chem 26:279-402, 1972
11. Brange J, Ribel U, Hansen JF, Dodson G, Hansen MY, Havelund S, Melberg SG, Norris F, Noons K, Snel L, Sörensen AR, Voigt HO: Monomeric insulins obtained by protein engineering and their medical implications. Nature 333:679-682, 1988
12. Drejer K: The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. Diabetes Metab Rev 8:259-286, 1992
13. Kang S, Brange J, Burch A, Volund A, Owens DR: Absorption kinetics and action profiles of subcutaneously administered insulin analogues (AspB9 GluB27; AspB10; AspB28) in healthy subjects. Diabetes Care 14:1057-1065, 1991
14. Kang S, Creagh FM, Peters JR, Brange J, Volund A, Owens DR: Comparison of subcutaneous soluble human insulin and insulin analogues (AspB9 GluB27; AspB10; AspB28) on meal related plasma glucose excursions in type 1 diabetic subjects. Diabetes Care 14:571-577, 1991
15. Heinemann, L, Heise T, Jorgensen LN, Starke AAR: Action profile of the rapid acting insulin analogue: human insulin B28 Asp. Diabet Med 10:535-539, 1993
16. Heinemann L, Kapitza C, Starke AAR, Heise T: Time-action profile of the insulin analogue B28Asp. Diabet Med 13:683-684, 1996
17. Kang S, Creagh FM, Ara J, Owens DR, Peters JR: Insulin analogues and human insulin: near-equivalent in vivo biological activity in healthy males in spite of widely different in vivo potencies (Abstract). Diabetes 40 (Suppl. 1):243A, 1991
18. Anderson JH, Brunelle RL, Koivisto VA, Pfützner A, Trautmann ME, Vignati L, DiMarchi R: Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Diabetes 46:265-270, 1997
19. Jorgensen LN, Nielsen FS: Timing of premeal insulins in diabetic patients on a multiple daily injection regimen: a questionnaire study (Abstract). Diabetologia 33 (Suppl. 1): 116A, 1990
20. Berger M, Heinemann L: Are presently available insulin analogues clinically beneficial? Diabet Med 40 (Suppl. 2):S91-S96, 1997
21. Heinemann L: Do insulin treated diabetic patients use an injection-meal interval in daily life? Diabet Med 12:449-450, 1995
22. Heinemann L, Starke AAR, Hohmann A, Berger M: Timing between the subcutaneous administration of insulin and consumption of a carbohydrate rich meal. Horm Metab Res 10 (Suppl. 26):137-139, 1992
23. Home P, Barriocanal L, Lindholm A: Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. Eur Clin Pharm. In press
24. Torlone E, Pampanelli S, Lalli C, del Sindaco P, di Vincenzo A, Rambotti AM, Modarelli F, Epifano L, Kassi G, Perriello G, Brunetti P, Bolli G: Effects of the short-acting insulin analog [Lys(B28), Pro(B29)] on postprandial blood glucose control in IDDM. Diabetes Care 19:945-952, 1996